Showing results (81-90 of 148) with videos related to
Sort By:
Pageof 15
Journal of Drug Targeting|September 3, 2016
Pieter Cullis' quest for a lipid-based, fusogenic delivery system for nucleic acid therapeutics: success with siRNA so what about mRNA?Ying K Tam, Thomas D Madden, Michael J HopeACS Nano|June 5, 2015
Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid NanoparticlesSrinivas Ramishetti, Ranit Kedmi, Meir Goldsmith, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|July 21, 2018
Dexamethasone prodrugs as potent suppressors of the immunostimulatory effects of lipid nanoparticle formulations of nucleic acidsSam Chen, Josh Zaifman, Jayesh A Kulkarni, et al.Analytical Chemistry|May 29, 2026
Direct Counting of mRNA Copies Inside Individual Lipid Nanoparticles Using In Situ Lysis and LabelingSadie Graves, Martin Jasinski, Erik Olsén, et al.Nanomedicine : Nanotechnology, Biology, and Medicine|June 16, 2012
Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNAPaulo J C Lin, Yuen Yi C Tam, Ismail Hafez, et al.ACS Nano|September 11, 2025
A Machine Learning Assisted Tool and Numerical Model for Analyzing Lipid NanoparticlesOwen Yuk Long Ip, Harrison D E Fan, Yao Zhang, et al.International Journal of Pharmaceutics|August 14, 2022
Development of a child-friendly oral drug formulation using liposomal multilamellar vesicle technologyNojoud Al Fayez, Roland Böttger, Sreemoyee Ghosh, et al.Molecular Therapy. Nucleic Acids|December 5, 2013
Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the BrainRavi L Rungta, Hyun B Choi, Paulo Jc Lin, et al.International Immunology|June 9, 2009
Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticlesGhania Chikh, Susan D de Jong, Laura Sekirov, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2015
siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate CancerYoshiaki Yamamoto, Paulo J C Lin, Eliana Beraldi, et al.Pageof 15